Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks -- and the track record of the firm behind them -- so individuals can make better investing decisions.

In addition to following professional banks, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 120,000 members, many of whom demonstrate better investing insight than published analysts do.

Enough top-performing CAPS members have turned bullish on GlaxoSmithKline (NYSE:GSK) recently to upgrade it from its long-held four-star rank to a tip-top five stars. A total of 948 members have weighed in on GlaxoSmithKline, with many of them offering analysis and commentary explaining the recent optimism.

Many investors see big health-care firms like Pfizer (NYSE:PFE) and GlaxoSmithKline as safe stocks to beat the financial crisis, despite shares being beaten down over the past year. Pharmas like Glaxo, Novartis (NYSE:NVS), and Johnson & Johnson (NYSE:JNJ) are sitting on billions in cash and producing billions in free cash flow every year. While tight credit markets could strain smaller development-stage companies like Exelixis (NASDAQ:EXEL), cash gives big pharma the advantage in terms of flexibility for acquisitions, marketing partnerships, or clinical trial work.

Glaxo is hoping to emerge stronger from this volatile period as well. In a move to build presence in emerging markets, Glaxo announced it will purchase a unit of Bristol-Myers Squibb (NYSE:BMY) in Egypt for $210 million in a bid to become the leading pharmaceutical company in Egypt. And according to its presentation at the annual shareholders' meeting in May, Glaxo has the most drugs in mid- to late-stage development of any drugmaker in the world, ahead of even Sanofi-Aventis (NYSE:SNY) and Pfizer.

Having Warren Buffett on board as an owner and providing a dividend yield of 5.2% also give many investors confidence in Glaxo's long-term prospects. In CAPS, 94% of the members rating the company expect it to outperform the market.

To see what the very best CAPS analysts are saying now about GlaxoSmithKline -- as well as other winning stocks they are picking -- head on over to CAPS and have a look.

More Foolishness:

Always looking ahead, the Motley Fool Rule Breakers service has recommended Exelixis to subscribers. To see what other rule-breaking stocks David Gardner is picking today, take a free 30-day trial.

Fool contributor Dave Mock recently upgraded the cat food to seafood medley, but is holding off on the Fancy Feast. He owns shares of Pfizer and Johnson & Johnson. Pfizer, Johnson & Johnson, and Glaxosmithkline are Income Investor picks. Pfizer is also an Inside Value recommendation. Exelixis is a Rule Breakers selection. The Fool owns shares of Pfizer and Exelixis. The Fool's disclosure policy made it through school pitching quarters.